Fresenius Kabi is the market leader in infusion therapy and clinical nutrition in Europe and holds leading positions in important countries of Latin America and the Asia-Pacific region. Within I.V. generic drugs, Fresenius Kabi counts among the leading suppliers in the US market.
Fresenius Kabi is focused on the therapy and care of critically and chronically ill patients inside and outside the hospital. With a corporate philosophy of "Caring for Life," the company’s goal is to improve the patient's quality of life.
To the homepage of Fresenius Kabi
Fresenius Kabi provides:
- Infusion Therapy
- Parenteral Nutrition
- Enteral Nutrition
- Infusion Technology
- Transfusion Technology
- Ambulatory Care
Fresenius Kabi has more than 22,500 employees worldwide and a global network of around 55 sales organizations and around 60 production sites. In 2010, Fresenius Kabi achieved sales of € 3,672 million and an operating profit (EBIT) of € 737 million.
Fresenius Kabi AG is a 100% subsidiary of Fresenius SE & Co. KGaA.